PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine- induced colorectal carcinogenesis in male Fischer F344 rats

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 995-999

  Kankesan, Janarthanan ^a   Laconi, Ezio ^c   Medline, Alan ^a   Thiessen, Jake J ^b   Ling, Victor ^d   Rao, Prema M ^a   Rajalakshmi, Srinivasan ^a   Sarma, Dittakavi S R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Colorectal cancer; P glycoprotein; PSC 833

Indexed keywords

1,2 DIMETHYLHYDRAZINE; GLYCOPROTEIN P; OROTIC ACID; VALSPODAR;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CARCINOMA; DRUG EFFECT; DRUG INHIBITION; MALE; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT; STUDENT T TEST; TUMOR VOLUME;

1,2-DIMETHYLHYDRAZINE; ADENOCARCINOMA; ANIMALS; BODY WEIGHT; COLORECTAL NEOPLASMS; CYCLOSPORINS; EATING; MALE; P-GLYCOPROTEIN; RATS; RATS, INBRED F344;

EID: 33645799106     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chaudhary PM and Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94, 1991.
2. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica Biophysica Acta 455: 152-162, 1976.
3. Goldstein LJ: MDR1 gene expression in solid tumours. Eur J Cancer 32A: 1039-1050, 1996.
4. Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP and Scheper RJ: Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 52: 450-454, 1999.
5. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB et al: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
6. Ferry DR: Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Therapeut 36: 29-40, 1998.
7. Bradley G, Sharma R, Rajalakshmi S and Ling V: P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154-5161, 1992.
8. Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Backer FF and Kuo MT: Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinogen 8: 67-73, 1993.
9. Zhang F, Riley J and Gant TW: Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors. Lab Investig 75: 413-426, 1996.
10. Mochida Y, Taguchi K, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, Kuwano M and Wada M: The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice. Carcinogenesis 24: 1219-1224, 2003.
11. Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Kondo T and Hirohashi S: Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 63: 895-901, 2003.
12. Kankesan J, Vanama R, Yusuf A, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S and Sarma DSR: Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 25: 425-430, 2004.
13. Kankesan J, Yusuf A, Laconi E, Vanama R, Bradley G, Thiessen JJ, Ling V, Rao PM, Rajalakshmi S and Sarma DSR: Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats. Carcinogenesis 24: 1977-1984, 2003.
14. Laconi E, Denda A, Rao PM, Rajalakshmi S, Pani P and Sarma DSR: Studies on liver tumor promotion in the rat by orotic acid: dose and minimum exposure time required for dietary orotic acid to promote hepatocarcinogenesis. Carcinogenesis 14: 1771-1775, 1993.
15. Hamilton SR and Aaltonen LA: World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Digestive System. Published by IARC, 2000.
16. Greene FL, Lamb LS and Barwick M: Colorectal cancer in animal models - a review. J Surg Res 43: 476-487, 1987.
17. Heyer J, Yang K, Lipkin M, Edelmann W and Kucherlapati R: Mouse models for colorectal cancer. Oncogene 18: 5325-5333, 1999.
18. Lehne G, Sorensen DR, Tjonnfjord GE, Beiske C, Hagve TA, Rugstad HE and Clausen OP: The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 16: 2388-2394, 2002.
19. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A and Jaffrezou JP: Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 12: 101-109, 1998.
20. Cabot MC, Giuliano AE, Han TY and Liu YY: SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 59: 880-885, 1999.
21. Lehne G, Morkrid L, den Boer M and Rugstad HE: Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int J Clin Pharmacol Therapeut 38: 187-195, 2000.
22. Smyth MJ, Krasovskis E, Sutton VR and Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024-7029, 1998.
23. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I and Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 256: 1120-1122, 1987.
24. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS and Roepe PD: Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36: 11169-11178, 1997.
25. Schmelz EM, Sullards MC, Dillehay DL and Merrill AH Jr: Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. J Nutr 130: 522-527, 2000.
26. Symolon H, Schmelz EM, Dillehay DL and Merrill AH Jr: Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2- dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 134: 1157-1161, 2004.
27. Silins I, Nordstrand M, Hogberg J and Stenius U: Sphingolipids suppress preneoplastic rat hepatocytes in vitro and in vivo. Carcinogenesis 24: 1077-1083, 2003.
28. Laurier C, Tatematsu M, Rao PM, Rajalakshmi S and Sarma DSR: Promotion by orotic acid of liver carcinogenesis in rats initiated by 1,2-dimethylhydrazine. Cancer Res 44: 2186-2191, 1984.